Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$1.82 - $15.10
Next Earnings Date
May 07 2025
Next Earnings Date
May 07 2025
Last Price
Market Cap | $296.14M |
EV | $872.74M |
Shares Outstanding | 54.34M |
Beta | 2.15 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $13.50 |
P/E 2025E | 78.78x |
P/Revenue 2025E | 0.32x |
Revenue | -16.50% |
EPS | - |
Operating Cash Flow | -43.30% |
Free Cash Flow | -28.10% |
Revenue | 7.50% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | 104.20% |
Gross Margin 2025E | 49.60% |
Net Profit Margin 2025E | 0.47% |
ROE 2025E | 22.66% |
ROCE 2024 | -33.67% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Emergent BioSolutions Inc.
EBS
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Papa, Joseph
Employees
900
Website
www.emergentbiosolutions.comIPO Date
2006-11-15
Headquarters
400 Professional Drive, Suite 400, Gaithersburg, Maryland, 20879, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved